IL BCCP Questions.

Slides:



Advertisements
Similar presentations
Update:Pap Smear Guidelines
Advertisements

In the name of God Isfahan medical school Shahnaz Aram MD.
MANAGEMENT OF THE ABNORMAL PAP SMEAR
Cervical Cancer. Dr. Swapna Chaudhary M.S. (MUM) Consultant Obstetrician & Gynaecologist Infertility Specialist.
Cervical Cancer DR KHALID H. WALI SAIT (FRCSC) ASSOCIATE PROFESSOR OF GYNECOLOGICAL ONCOLOGY King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Kentucky Women’s Cancer Screening Program JULY 2013 CCSG CHANGES.
1 BCCCP MBCIS Data Webinar December 7, Featuring Ann Garvin, MS, CNM EJ Siegl, MA, OCN, RN Susan Harris, Ph. D. Cathy Blaze.
Cervical Cancer American Cancer Society Georgia Department of Human Resources The University of Georgia Cooperative Extension Service.
Updates on Pap Smear Guidelines 2014
ASHLYN SAVAGE, MD, MSCR ASSOCIATE PROFESSOR OBSTETRICS AND GYNECOLOGY MEDICAL UNIVERSITY OF SOUTH CAROLINA Managing Abnormal Pap Smears: Incorporating.
Comparison of HPV Testing and Spectroscopy Combined with Cytology for the Detection of High- grade Cervical Neoplasia C Werner, W Griffith III, R Ashfaq,D.
Cervical Cancer Cervical dysplasia Cervical cancer Causes Risk factors
Screening for Cervical Cancer
Management of Women with CIN 1 or LSIL
Benign and premalignant disease of the cervix
Cervical Cancer: Prevention and Treatment
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
Clinical Uses of HPV DNA Testing
 Cervical cancer is a malignant tumour deriving from cells of the "cervix uteri", which is the lower part of uterus.  Begins in the lining of the cervix.
Case Presentations: Pre-Invasive Cervical Neoplasia
BREAST AND CERVICAL CANCER CONTROL PROGRAM Emily Vance Nursing 250.
Management of Gynaecological Cancers. Gynaecological Cancers in NSW 1180 new cases in % of all new cancer diagnoses Crude incidence rate 35.3 per.
Cervical Cancer Screening
Screening Tests for Brest & Cervical Cancer
Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.
CANCER CERVIX A PREVENTABLE CANCER Dr NEETA DHABHAI Sr Consultant. – Gynaecologist Member Expert - Indian Cancer Winners’ Association
Academic Year MSIII Ob/Gyn Clerkship Self-Directed Study
Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.
Abnormal Pap in Pregnancy Alexander Burnett, MD Division Gyn Oncology, UAMS April, 2006.
SoftPAP® A Novel Collection Device for Cervical Cytology.
Endometrial Carcinoma
Component 3-Terminology in Healthcare and Public Health Settings
Current guidelines for Cervical Cancer Screening
Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Screening.
In the Name of God. Screening of Cervical Cancer Pap smear and colposcopy F.Behnamfar Gynecology Oncology Fellowship Associate Professor Isfahan University.
KATIE OSTROM PAPS, ABORTION, AND VACUUM DELIVERY.
Endometrial Cancer By Jessica Hall. Symptoms Unusual vaginal bleeding or discharge Difficult or painful urination Pain during intercourse Pain in the.
Report from Cervical Cancer Committee Maryland State Cancer Plan Strategies for Improving the Control of Cervical Cancer in Maryland.
Adult Medical-Surgical Nursing
Anal Cancer - Case 1  62 years old woman with 6 months history of anal pain  Clinically T 3 squamous cell carcinoma growing anteriorly  Which staging.
Cervical cancer is the third most common cancer in women worldwide. Cervical cancer is a disease that develops quite slowly and begins with a precancerous.
Board Review Clinical Epi and Prevention Cristin Colford, MD June 15 th, 2008.
Cervical Cancer Screening Guidelines Update
Sarah Feldman MD MPH Co-Director Ambulatory Gynecologic Oncology Brigham & Women’s Hospital Dana Farber Cancer Institute Lowell Cancer Center Associate.
Cytologic Findings in Type 2 Cervical Carcinomas: Some Cervical Carcinomas are more Difficult to Prevent with Screening R. Marshall Austin MD,PhD Magee-Womens.
Cervical Cancer Screening and Sexually Transmitted Infection Case Study PCP version
Premalignant lesions of the cervix. Applied anatomy.
COLPOSCOPY QUESTIONS Michael R. Downs M.D. October 2004.
2006 ASCCP Consensus Guidelines Anne L. Kittendorf, MD FAAFP Assistant Professor University of Michigan Department of Family Medicine.
Kathy A. King, MD Assistant Professor of OB/GYN Medical Director, PPWI
To pap or not to pap: and what to do when you do Kimberly Swan MD Minimally Invasive Gynecologic Surgery Assistant Professor Ob/Gyn University of Kansas.
Cervical Cancer: Experiences from a Cohort of HIV-infected Women Pascoe M, Magure T, Mudhokwani P et al Abstract: MOAB0202.
Dr. Ahmed jasim Ass.Prof.MBChB-DOG-FICMS COSULTANT OF GYN. & OBST. COSULTANT OF GYN. & OBST.
Collaboration with Community Partners to Provide Breast and Cervical Cancer Services to the Underserved University of Texas Health Sciences Center at Tyler.
Cytopathology Feb
Cervical Screening: Do I Really Need a Pap Test April 2010.
Cervical Cancer Screening
Trreatment of Preinvasive Lesions
Cervical Cancer Colposcopy & Treatment
Risk factors for cervical intraepithelial neoplasia recurrence after loop electrosurgical excision procedure in HIV-1-infected and non-infected women.
Dr N Shailaja Dr Pradeep
Male and Female Reproductive Health Concerns
Colposcopy triage. Satisfactory colposcopy is defined as complete visualization of the squamocolumnar epithelium, which comprises the cervical region most.
Updates on Pap Smear Guidelines 2014
AGC&AIS Setareh Akhavan M.D Gynecologist Oncologist
Cervical Screening for Dysplasia and Cancer in Patients with HIV
What is a Pap smear? A Pap smear (also known as the Pap test) is a medical procedure in which a sample of cells from a woman's cervix (the end of the uterus that.
SH-sheikhhasani Gyn-oncologist
Presentation transcript:

IL BCCP Questions

Managing treated CIN2+ A client has treatment for CIN2 or CIN3, co-testing at 12months and 24 months is recommended. If both co-tests are negative, retesting in 3 years is recommended. What if the client has had 1 or 2 negative pap tests in the last 2 years but no HPV test, should we co-test for 2 years and then return to screening in 3 years?  

Managing treated CIN2+ A client has treatment for CIN2 or CIN3. Client was out of program for 2 years then comes back to IBCCP, we have no record of paps or hpv during this time. Should this client be co-tested this year and next year?

Managing remotely treated CIN2+ after hysterectomy New client age 58 reported hysterectomy due to “cysts” and no paps since.  Obtained records for hysterectomy which was done 5/25/89.  Per History and Physical hysterectomy was done due to severe dysplasia of cervix.  Pathology results were severe dysplasia with free surgical margins.  The cervix was removed.  Should this client have a pap and hpv?

No diagnostic excision for cancer The client was referred into the program with a Pap with an ASC-H (PT4) result on 1/14/2013.  On 2/12/2013 the client had a colposcopy with biopsy and ECC.  The results of the colposcopy were “invasive poorly differentiated non-keratinizing squamous cell carcinoma at both the 2 o’clock and 10 o’clock uterine cervix”.  This was the final diagnosis and the client was approved for a medical card and later received radiation and chemo. Why didn’t they do a diagnostic excisional procedure?

AGC in women 25-29yo Occasionally, I saw a few patients between 25-29y/o with AGC.  Since these patients can have endometrial cancer too and we do not want to miss that, should we do Colpo only or Colpo with EMB? If the EMB is done based on the patient’s history and risk factors, are these risk factors reliable? Is there any harm with doing the EMB at this young age range? Since AGC could also be an indicator for other cancers of the female reproductive system, should we do more extensive tests for these patients such as pelvic ultrasound, EMB, etc…?

LSIL without CIN 49 y/o with a 2 year history of LSIL pap with benign colpo w/bx. 5/2011  LSIL Pap 5/2011  Colpo w/bx benign 11/2011  Negative Pap 6/2012  LSIL Pap Client refused colpo 11/2012  LSIL Pap 1/2013  Colpo w/bx benign 3/2014  LSIL HPV positive Provider ordering treatment: cryocautery

LSIL without CIN 44 year old woman with a history of abnormal paps. 12/15/10 – Pap LSIL/+HPV 1/12/11 – colpo/biopsy negative 5/30/12 – Pap ASC-US/+HPV 6/28/12 – colpo/biopsy CIN1 1/10/13 – Pap LSIL 2/26/13 – colpo/biopsy CIN1 8/28/13 – Pap negative She is now scheduled for cotesting this month to follow the new algorithm stating women with CIN1 preceded by “Lesser Abnormalities” should have cotesting at 12 months. Since her follow-up pap after her 2/26/13 biopsy was only six months and didn’t include HPV we advised her to have cotesting at 12 months.